Selected article for: "anticancer strategy and novel anticancer strategy"
Author: Luo, Bangyu; Li, Jixi; Hou, Xianhua; Yang, Qiao; Zhou, Yi; Ye, Jun; Wu, Xiaocheng; Feng, Yimei; Hu, Tianyu; Xu, Zhi; He, Ying; Sun, Jianguo
Title: Indications for and contraindications of immune checkpoint inhibitors in cancer patients with coronavirus disease 2019 vaccination
  • Cord-id: 96o9qhl6
  • Document date: 2021_6_30
    • ID: 96o9qhl6
    Snippet: The novel coronavirus disease 2019 (COVID-19) pandemic has lasted over 1 year and will not disappear in a short time. There is no specific remedy against the virus as yet. Vaccination is thus far one of the most important strategies for preventing COVID-19. Cancer patients with COVID-19 have a higher mortality because of immunosuppression. Immune checkpoint inhibitors (ICIs) are a novel anticancer strategy for blocking inhibitory pathways, which are related to the immune response. There is a que
    Document: The novel coronavirus disease 2019 (COVID-19) pandemic has lasted over 1 year and will not disappear in a short time. There is no specific remedy against the virus as yet. Vaccination is thus far one of the most important strategies for preventing COVID-19. Cancer patients with COVID-19 have a higher mortality because of immunosuppression. Immune checkpoint inhibitors (ICIs) are a novel anticancer strategy for blocking inhibitory pathways, which are related to the immune response. There is a question regarding whether COVID-19 vaccination and ICI treatment impact each other in cancer patients. This review explores both sides of the relationship between ICI treatment and COVID-19 vaccination and suggests good efficacy and safety of ICI treatment after COVID-19 vaccination as well as little impact on the virus protection and toxicity associated with COVID-19 vaccination during ICI treatment.

    Search related documents:
    Co phrase search for related documents
    • acceptable safety and low incidence: 1
    • acceptable safety and lung cancer: 1, 2
    • acceptable safety and lung damage: 1
    • acute viral low respiratory tract infection and low respiratory tract infection: 1
    • low incidence and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8